5.42 USD
-0.33 (-5.74%)
5.4185 USD
0 (-0.03%)
Taking everything into account, MDXG scores 6 out of 10 in our fundamental rating. MDXG was compared to 525 industry peers in the Biotechnology industry. MDXG is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. A decent growth rate in combination with a cheap valuation! Better keep an eye on MDXG. This makes MDXG very considerable for value investing!
1. Profitability
1.1 Basic Checks
- MDXG had positive earnings in the past year.
- MDXG had a positive operating cash flow in the past year.
- In multiple years MDXG reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
1.2 Ratios
- With an excellent Return On Assets value of 12.80%, MDXG belongs to the best of the industry, outperforming 94.34% of the companies in the same industry.
- MDXG's Return On Equity of 17.09% is amongst the best of the industry. MDXG outperforms 95.09% of its industry peers.
- MDXG has a Return On Invested Capital of 15.15%. This is amongst the best in the industry. MDXG outperforms 95.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MDXG has a better Profit Margin (10.38%) than 91.13% of its industry peers.
- MDXG has a better Operating Margin (13.73%) than 92.83% of its industry peers.
- In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
- MDXG has a Gross Margin of 81.99%. This is amongst the best in the industry. MDXG outperforms 85.47% of its industry peers.
- MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDXG is creating some value.
- MDXG has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for MDXG has been increased compared to 5 years ago.
- Compared to 1 year ago, MDXG has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 8.29 indicates that MDXG is not in any danger for bankruptcy at the moment.
- MDXG's Altman-Z score of 8.29 is fine compared to the rest of the industry. MDXG outperforms 79.81% of its industry peers.
- MDXG has a debt to FCF ratio of 0.27. This is a very positive value and a sign of high solvency as it would only need 0.27 years to pay back of all of its debts.
- MDXG's Debt to FCF ratio of 0.27 is amongst the best of the industry. MDXG outperforms 95.47% of its industry peers.
- A Debt/Equity ratio of 0.07 indicates that MDXG is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.07, MDXG is not doing good in the industry: 60.94% of the companies in the same industry are doing better.
- Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 8.29 |
ROIC/WACC1.73
WACC8.76%
2.3 Liquidity
- A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
- With a Current ratio value of 4.41, MDXG perfoms like the industry average, outperforming 51.13% of the companies in the same industry.
- A Quick Ratio of 3.95 indicates that MDXG has no problem at all paying its short term obligations.
- MDXG has a Quick ratio (3.95) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
- The earnings per share for MDXG have decreased strongly by -35.71% in the last year.
- The Revenue has grown by 14.77% in the past year. This is quite good.
- Measured over the past years, MDXG shows a small growth in Revenue. The Revenue has been growing by 3.11% on average per year.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
- The Earnings Per Share is expected to grow by 16.54% on average over the next years. This is quite good.
- The Revenue is expected to grow by 14.49% on average over the next years. This is quite good.
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 15.06, which indicates a correct valuation of MDXG.
- 96.23% of the companies in the same industry are more expensive than MDXG, based on the Price/Earnings ratio.
- MDXG is valuated rather cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 21.69 indicates a rather expensive valuation of MDXG.
- 93.02% of the companies in the same industry are more expensive than MDXG, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, MDXG is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.06 | ||
| Fwd PE | 21.69 |
4.2 Price Multiples
- MDXG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDXG is cheaper than 96.98% of the companies in the same industry.
- MDXG's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDXG is cheaper than 97.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.01 | ||
| EV/EBITDA | 9.89 |
4.3 Compensation for Growth
- MDXG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MDXG has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as MDXG's earnings are expected to grow with 16.54% in the coming years.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
5. Dividend
5.1 Amount
- No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.42
-0.33 (-5.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners71.94%
Inst Owner Change0.21%
Ins Owners1.79%
Ins Owner Change-0.11%
Market Cap802.70M
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (129.52%)
Short Float %3.16%
Short Ratio4.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.15%
EPS NY rev (1m)0%
EPS NY rev (3m)29.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.06 | ||
| Fwd PE | 21.69 | ||
| P/S | 2.04 | ||
| P/FCF | 12.01 | ||
| P/OCF | 11.83 | ||
| P/B | 3.36 | ||
| P/tB | 3.85 | ||
| EV/EBITDA | 9.89 |
EPS(TTM)0.36
EY6.64%
EPS(NY)0.25
Fwd EY4.61%
FCF(TTM)0.45
FCFY8.32%
OCF(TTM)0.46
OCFY8.45%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.32
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 8.29 |
F-Score6
WACC8.76%
ROIC/WACC1.73
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year63.46%
EBIT Next 3Y22.08%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
Can you provide the valuation status for MIMEDX GROUP INC?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.
What is the earnings growth outlook for MIMEDX GROUP INC?
The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to grow by 47.72% in the next year.